[EN] PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES [FR] COMPOSÉS PYRROLOSULFONAMIDES POUR LA MODULATION DE L'ACTIVITÉ DU RÉCEPTEUR ORPHELIN GAMMA APPARENTÉ AU RÉCEPTEUR NUCLÉAIRE ORPHELIN RAR (ROR-GAMMA, NR1F3) ET POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES CHRONIQUES ET AUTO-IMMUNES
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
申请人:BENAZET ALEXANDRE
公开号:US20130079337A1
公开(公告)日:2013-03-28
The invention relates to compounds corresponding to formula (I)
in which R1, R2 and R3 are as defined in Claim
1
, and also to the process for preparing them and to their therapeutic use.
ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
申请人:Enanta Pharmaceuticals, Inc.
公开号:US20180099957A1
公开(公告)日:2018-04-12
The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
申请人:REN Pingda
公开号:US20120149701A1
公开(公告)日:2012-06-14
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
The subject invention relates to novel P2X
3
receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X
3
receptor subunit modulator.